In Reply: The letters from Drs Tenenbaum and Fisman and Drs Lim and Wong address 2 common arguments for the use of fibrates. In the United States, most of the fibrate sales are for formulations of fenofibrate. There are 2 large trials that have failed to show that fenofibrate reduces risk and none that show benefit. In ACCORD, the prespecified subgroup analysis to evaluate the tertile of the highest triglyceride concentration (≥204 mg/dL)/lowest high-density lipoprotein level (≤34 mg/dL) failed to show that fenofibrate was statistically significantly different from the comparison group.1 The meta-analysis by Sacks et al cited by Tenenbaum and Fisman performed a post hoc analysis of 5 fibrate trials that used different fibrates, employed different lipid profile cutoffs (triglyceride, >180 to ≥204 mg/dL; high-density lipoprotein, ≤34 to <50 mg/dL), and were conducted in different prevention eras.2 These analyses should be viewed as hypothesis generating. Our analysis of the evidence is consistent with the recent American Heart Association scientific statement that says that the effect of fibrates on patient risk is debatable and recommends lifestyle modification with diet and exercise as initial management in these types of patients, with fibrate therapy only recommended in those with triglyceride concentrations of 500 mg/dL or greater.3
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.